Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP-007
- Development stage
- Unknown
- Lead developer
- Sunny Pharmtech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SP-007 is a small molecule oral tablet formulation currently under development by Sunny Pharmtech, a specialty pharmaceutical company and Contract Development and Manufacturing Organization (CDMO). The drug is identified as a high-potency anti-cancer agent (Occupational Exposure Band 5) specifically targeting melanoma. Based on its development stage in Bioequivalence (BE) studies, SP-007 is likely a generic version of an established oral melanoma therapy. It is being developed alongside SP-008, another melanoma candidate in capsule form, suggesting a focus on the BRAF/MEK inhibitor pathways commonly utilized in targeted melanoma treatment.
Beyond the preview
Go deeper on SP-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP-007.